Budesonide Structural Formula (Image 1)
Budesonide Suspension
Product Images NDC 0093-6817
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 0093-6817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Image 10)
This is a medication called Budesonide Inhalation Suspension. Each unit-dose ampule delivers 2 mL of a sterile suspension containing 1 mg of micronized budesonide. It is for oral inhalation use only and not for injection. The medication comes in 6 pouches with 5 2 mL ampules each, for a total of 30 unit-dose ampules. It should only be used in a jet nebulizer and not in an ultrasonic nebulizer. The inactive ingredients include citric acid monohydrate, disodium edetate, polysorbate 80, sodium chloride, tri-sodium citrate dihydrate, and water for injection. The medication is manufactured in England by Norton Healthcare Limited and brought to the United States by Teva Pharmaceuticals USA, Inc. The lot/exp coding area is available.*
Figure 1: A 12 Week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 2)
The text is describing a clinical trial for a medication aimed at reducing nighttime asthma symptoms. The trial measured the mean change from baseline symptoms over a 12-week period, with patients taking either placebo, 0.25mg, 0.5mg, or 1.0mg once daily. The p-values for each dose were also provided.*
Figure 2: A 12 Week Trial In Pediatric Patients Previously Maintained On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 3)
Figure 3: A 12 Week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Image 4)
This appears to be a table or a chart showing the mean change from baseline nighttime asthma symptoms for different doses of a medication over a period of 12 weeks. The medication was compared to a placebo. The text notes the different doses and their frequency, as well as the p-values for each dose.*
Figure 1 (Image 5)
Figure 2 (Image 6)
Figure 3 (Image 7)
Figure 4 (Image 8)
1 (Image 9)
This is a set of instructions for the proper use and storage of Budesonide Inhalation Suspension. The user is advised to follow instructions given by a physician and not to discard the foil envelope until all ampules are used. The user should also use the contents of an ampule immediately after opening it. The unopened ampules should be stored upright in the carton in the foil envelope and protected from light. The instructions provide a step-by-step guide on how to use the product and direct the user to refer to the enclosed Patient Instructions.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
